The Paediatric Rheumatology International Trials Organization (PRINTO)

Nicolino Ruperto, A. Bazso, A. Ravelli, C. Malattia, G. Filocamo, A. Pistorio, A. L. Rodriguez Lozano, S. Viola, A. Martini

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

In this review we describe an international project, conducted by the Paediatric Rheumatology International Trials Organization (PRINTO) that was aimed to identify, validate and promulgate core sets of measures and a definition of improvement for the evaluation of response to therapy in clinical trials and in daily clinical practice in patients with juvenile systemic lupus erythematosus (JSLE). The following clinical measures were included in the PRINTO core set of outcome measure for the evaluation of response to therapy: 1) physician's global assessment of disease activity; 2) global disease activity measure; 3) 24-hour proteinuria; 4) parent's global assessment of the overall patient's well-being; 5) health-related quality of life assessment. The measures included in the core set were found to be feasible and not redundant, to have good construct validity, discriminative ability, internal consistency, with fair responsiveness to clinically important change in disease activity, and to be associated strongly with treatment outcome. In order to be classified as responder to a given treatment, a patient should demonstrate at least 50% improvement from baseline in any two of the five core set measures with no more than one of the remaining worsening by more than 30%. This definition is now known as the 'PRINTO/American College of Rheumatology (ACR) provisional criteria for JSLE'. The proposed core set and definition of improvement incorporate clinically meaningful change in a composite endpoint for the evaluation of global response to therapy in JSLE. The definition is now proposed for use in JSLE clinical trials, and may help physicians to decide if a child with SLE has responded adequately to therapy.

Original languageEnglish
Pages (from-to)670-676
Number of pages7
JournalLupus
Volume16
Issue number8
DOIs
Publication statusPublished - 2007

Fingerprint

Rheumatology
Systemic Lupus Erythematosus
Organizations
Pediatrics
Clinical Trials
Physicians
Therapeutics
Aptitude
Proteinuria
Parents
Quality of Life
Outcome Assessment (Health Care)

Keywords

  • Clinical trials
  • Juvenile systemic lupus erythematosus
  • Response to therapy

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

The Paediatric Rheumatology International Trials Organization (PRINTO). / Ruperto, Nicolino; Bazso, A.; Ravelli, A.; Malattia, C.; Filocamo, G.; Pistorio, A.; Rodriguez Lozano, A. L.; Viola, S.; Martini, A.

In: Lupus, Vol. 16, No. 8, 2007, p. 670-676.

Research output: Contribution to journalArticle

Ruperto, Nicolino ; Bazso, A. ; Ravelli, A. ; Malattia, C. ; Filocamo, G. ; Pistorio, A. ; Rodriguez Lozano, A. L. ; Viola, S. ; Martini, A. / The Paediatric Rheumatology International Trials Organization (PRINTO). In: Lupus. 2007 ; Vol. 16, No. 8. pp. 670-676.
@article{2d1dbb9055d74f6f8c26f86a18ad53d7,
title = "The Paediatric Rheumatology International Trials Organization (PRINTO)",
abstract = "In this review we describe an international project, conducted by the Paediatric Rheumatology International Trials Organization (PRINTO) that was aimed to identify, validate and promulgate core sets of measures and a definition of improvement for the evaluation of response to therapy in clinical trials and in daily clinical practice in patients with juvenile systemic lupus erythematosus (JSLE). The following clinical measures were included in the PRINTO core set of outcome measure for the evaluation of response to therapy: 1) physician's global assessment of disease activity; 2) global disease activity measure; 3) 24-hour proteinuria; 4) parent's global assessment of the overall patient's well-being; 5) health-related quality of life assessment. The measures included in the core set were found to be feasible and not redundant, to have good construct validity, discriminative ability, internal consistency, with fair responsiveness to clinically important change in disease activity, and to be associated strongly with treatment outcome. In order to be classified as responder to a given treatment, a patient should demonstrate at least 50{\%} improvement from baseline in any two of the five core set measures with no more than one of the remaining worsening by more than 30{\%}. This definition is now known as the 'PRINTO/American College of Rheumatology (ACR) provisional criteria for JSLE'. The proposed core set and definition of improvement incorporate clinically meaningful change in a composite endpoint for the evaluation of global response to therapy in JSLE. The definition is now proposed for use in JSLE clinical trials, and may help physicians to decide if a child with SLE has responded adequately to therapy.",
keywords = "Clinical trials, Juvenile systemic lupus erythematosus, Response to therapy",
author = "Nicolino Ruperto and A. Bazso and A. Ravelli and C. Malattia and G. Filocamo and A. Pistorio and {Rodriguez Lozano}, {A. L.} and S. Viola and A. Martini",
year = "2007",
doi = "10.1177/0961203307079556",
language = "English",
volume = "16",
pages = "670--676",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "8",

}

TY - JOUR

T1 - The Paediatric Rheumatology International Trials Organization (PRINTO)

AU - Ruperto, Nicolino

AU - Bazso, A.

AU - Ravelli, A.

AU - Malattia, C.

AU - Filocamo, G.

AU - Pistorio, A.

AU - Rodriguez Lozano, A. L.

AU - Viola, S.

AU - Martini, A.

PY - 2007

Y1 - 2007

N2 - In this review we describe an international project, conducted by the Paediatric Rheumatology International Trials Organization (PRINTO) that was aimed to identify, validate and promulgate core sets of measures and a definition of improvement for the evaluation of response to therapy in clinical trials and in daily clinical practice in patients with juvenile systemic lupus erythematosus (JSLE). The following clinical measures were included in the PRINTO core set of outcome measure for the evaluation of response to therapy: 1) physician's global assessment of disease activity; 2) global disease activity measure; 3) 24-hour proteinuria; 4) parent's global assessment of the overall patient's well-being; 5) health-related quality of life assessment. The measures included in the core set were found to be feasible and not redundant, to have good construct validity, discriminative ability, internal consistency, with fair responsiveness to clinically important change in disease activity, and to be associated strongly with treatment outcome. In order to be classified as responder to a given treatment, a patient should demonstrate at least 50% improvement from baseline in any two of the five core set measures with no more than one of the remaining worsening by more than 30%. This definition is now known as the 'PRINTO/American College of Rheumatology (ACR) provisional criteria for JSLE'. The proposed core set and definition of improvement incorporate clinically meaningful change in a composite endpoint for the evaluation of global response to therapy in JSLE. The definition is now proposed for use in JSLE clinical trials, and may help physicians to decide if a child with SLE has responded adequately to therapy.

AB - In this review we describe an international project, conducted by the Paediatric Rheumatology International Trials Organization (PRINTO) that was aimed to identify, validate and promulgate core sets of measures and a definition of improvement for the evaluation of response to therapy in clinical trials and in daily clinical practice in patients with juvenile systemic lupus erythematosus (JSLE). The following clinical measures were included in the PRINTO core set of outcome measure for the evaluation of response to therapy: 1) physician's global assessment of disease activity; 2) global disease activity measure; 3) 24-hour proteinuria; 4) parent's global assessment of the overall patient's well-being; 5) health-related quality of life assessment. The measures included in the core set were found to be feasible and not redundant, to have good construct validity, discriminative ability, internal consistency, with fair responsiveness to clinically important change in disease activity, and to be associated strongly with treatment outcome. In order to be classified as responder to a given treatment, a patient should demonstrate at least 50% improvement from baseline in any two of the five core set measures with no more than one of the remaining worsening by more than 30%. This definition is now known as the 'PRINTO/American College of Rheumatology (ACR) provisional criteria for JSLE'. The proposed core set and definition of improvement incorporate clinically meaningful change in a composite endpoint for the evaluation of global response to therapy in JSLE. The definition is now proposed for use in JSLE clinical trials, and may help physicians to decide if a child with SLE has responded adequately to therapy.

KW - Clinical trials

KW - Juvenile systemic lupus erythematosus

KW - Response to therapy

UR - http://www.scopus.com/inward/record.url?scp=34548380925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548380925&partnerID=8YFLogxK

U2 - 10.1177/0961203307079556

DO - 10.1177/0961203307079556

M3 - Article

C2 - 17711906

AN - SCOPUS:34548380925

VL - 16

SP - 670

EP - 676

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 8

ER -